Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Income (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Operating Income readings, the most recent being $29.3 million for Q1 2026.

  • On a quarterly basis, Operating Income rose 120.52% to $29.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $38.3 million, a 342.44% increase, with the full-year FY2025 number at $22.3 million, up 148.92% from a year prior.
  • Operating Income hit $29.3 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from -$35.1 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $46.4 million in Q3 2022 to a low of -$35.1 million in Q4 2025.
  • Median Operating Income over the past 5 years was -$3.2 million (2023), compared with a mean of -$556235.3.
  • Biggest five-year swings in Operating Income: tumbled 23925.93% in 2024 and later skyrocketed 17330.77% in 2025.
  • Kiniksa Pharmaceuticals International's Operating Income stood at $6.0 million in 2022, then tumbled by 98.66% to $81000.0 in 2023, then tumbled by 23925.93% to -$19.3 million in 2024, then crashed by 82.07% to -$35.1 million in 2025, then skyrocketed by 183.29% to $29.3 million in 2026.
  • The last three reported values for Operating Income were $29.3 million (Q1 2026), -$35.1 million (Q4 2025), and $24.0 million (Q3 2025) per Business Quant data.